Warner Bryce M, Yates Jacob G E, Vendramelli Robert, Truong Thang, Meilleur Courtney, Chan Lily, Leacy Alexander, Pham Phuc H, Pei Yanlong, Susta Leonardo, Wootton Sarah K, Kobasa Darwyn
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada.
NPJ Vaccines. 2024 May 23;9(1):90. doi: 10.1038/s41541-024-00870-8.
The rapid development and deployment of vaccines following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to have saved millions of lives. Despite their immense success, there remains a need for next-generation vaccination approaches for SARS-CoV-2 and future emerging coronaviruses and other respiratory viruses. Here we utilized a Newcastle Disease virus (NDV) vectored vaccine expressing the ancestral SARS-CoV-2 spike protein in a pre-fusion stabilized chimeric conformation (NDV-PFS). When delivered intranasally, NDV-PFS protected both Syrian hamsters and K18 mice against Delta and Omicron SARS-CoV-2 variants of concern. Additionally, intranasal vaccination induced robust, durable protection that was extended to 6 months post-vaccination. Overall, our data provide evidence that NDV-vectored vaccines represent a viable next-generation mucosal vaccination approach.
据估计，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）出现后疫苗的快速研发和部署已挽救了数百万人的生命。尽管取得了巨大成功，但仍需要针对SARS-CoV-2以及未来出现的冠状病毒和其他呼吸道病毒的下一代疫苗接种方法。在此，我们使用了一种新城疫病毒（NDV）载体疫苗，该疫苗在融合前稳定的嵌合构象中表达原始SARS-CoV-2刺突蛋白（NDV-PFS）。经鼻内给药时，NDV-PFS保护叙利亚仓鼠和K18小鼠免受Delta和Omicron等SARS-CoV-2变异株的侵害。此外，鼻内接种诱导了强大、持久的保护作用，这种保护作用可延长至接种后6个月。总体而言，我们的数据表明，NDV载体疫苗是一种可行的下一代黏膜疫苗接种方法。
